logo
ResearchBunny Logo
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

Medicine and Health

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

P. Eijsvogel, P. Misra, et al.

This groundbreaking 44-week study explores UB-312, an innovative immunotherapeutic approach targeting pathological αSyn in Parkinson's disease patients. With safety and immunogenicity confirmed, findings indicate a significant reduction in αSyn seeds, paving the way for further development. Conducted by a team of experts, these promising results are a step forward in Parkinson's research.

00:00
00:00
Playback language: English
Citation Metrics
Citations
0
Influential Citations
0
Reference Count
0

Note: The citation metrics presented here have been sourced from Semantic Scholar and OpenAlex.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny